GlobeNewswire Inc | May 5, 2021 07:00AM EDT

May 05, 2021

SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (Annexon) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated autoimmune and neurodegenerative disorders of the body, brain and eye, announced that Douglas Love, Esq., President & Chief Executive Officer, will present at the Bank of America Securities 2021 Virtual Healthcare Conference on May 12, 2021 at 11:45 am EDT.

A live webcast of the event can be accessed under the Events & Presentations section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.

About Annexon, Inc.

Annexon is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. The companys pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to select indications, identify patients and measure target engagement and response to treatment. For more information, visit www.annexonbio.com.

Investor Contacts:Jennifer Lew, Chief Financial OfficerAnnexon Biosciencesjlew@annexonbio.com

Sara Michelmoresmichelmore@macbiocom.com

Media Contact:Miriam MasonAnnexon Biosciencesmmason@annexonbio.com